Literature DB >> 26032156

Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy.

Katrine R Christensen1, Casper Steenholdt1, Sine S Buhl1, Mark A Ainsworth1, Ole Ø Thomsen1, Jørn Brynskov1.   

Abstract

OBJECTIVES: Implementation of guidelines for prevention of infectious diseases during anti-TNFα therapy in patients with inflammatory bowel disease (IBD) is important but difficult. We investigated whether systematic information to health-care professionals about these guidelines improves patients' adherence.
METHODS: The study comprised three parts: (1) cross-sectional evaluation of baseline vaccination status in all IBD patients in anti-TNFα therapy (reference group; n=130); (2) prospective interventional study, where health-care professionals received systematic oral and written information about vaccination guidelines at baseline and at 2-month intervals for 6 months, followed by reassessment of vaccination status (intervention group; n=99); (3) cross-sectional evaluation of representative gastroenterologists' knowledge of guidelines (n=53). Outcomes were assessed by validated questionnaires.
RESULTS: Patients' adherence to vaccination guidelines increased significantly after a period of systematic information to health-care professionals. Hence, complete adherence increased from 5 to 26%, partial adherence from 38 to 56%, and complete non-adherence decreased from 57 to 18% (P<0.0001). Adherence to all individual vaccinations except human papilloma virus increased significantly (P≤0.0021). Improvement was independent of disease type and anti-TNFα agent. At baseline, only 8% of physicians could identify all elements in the reference guideline. Additional barriers reported by physicians were forgetfulness (32%) and insufficient consultation time (26%). Patient-perceived barriers were costs of vaccinations (35%) and forgetfulness (25%).
CONCLUSIONS: Gastroenterologists' limited knowledge of vaccination guidelines during anti-TNFα therapy can be overcome by systematic education of health-care professionals. This inexpensive and easily accessible intervention immediately results in markedly improved patient adherence. Remaining obstacles for adherence comprise high vaccination costs and forgetfulness.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26032156     DOI: 10.1038/ajg.2015.162

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  15 in total

1.  A prospective cohort study of practice guidelines in inflammatory bowel disease.

Authors:  W J Tremaine; W J Sandborn; E V Loftus; M L Kenan; T M Petterson; A R Zinsmeister; M D Silverstein
Journal:  Am J Gastroenterol       Date:  2001-08       Impact factor: 10.864

2.  Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy.

Authors:  Byron P Vaughn; Glen A Doherty; Shiva Gautam; Alan C Moss; Adam S Cheifetz
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

3.  A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD.

Authors:  Siddhartha Parker; Laura Chambers White; Chad Spangler; Jessica Rosenblum; Shannon Sweeney; Emily Homan; Steven P Bensen; L Campbell Levy; Maria Conception C Dragnev; Kristen Moskalenko-Locke; Pamela Rich; Corey A Siegel
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

Review 4.  Tumor necrosis factor inhibitors for inflammatory bowel disease.

Authors:  Ole Haagen Nielsen; Mark Andrew Ainsworth
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

5.  Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.

Authors:  Gil Y Melmed; Andrew F Ippoliti; Konstantinos A Papadakis; Tram T Tran; Jaime L Birt; Susie K Lee; Robert W Frenck; Stephan R Targan; Eric A Vasiliauskas
Journal:  Am J Gastroenterol       Date:  2006-06-30       Impact factor: 10.864

6.  Documented compliance with inflammatory bowel disease quality measures is poor.

Authors:  Joseph D Feuerstein; Jeffrey J Lewandowski; Manuel Martinez-Vazquez; Daniel A Leffler; Adam S Cheifetz
Journal:  Dig Dis Sci       Date:  2014-10-14       Impact factor: 3.199

Review 7.  Translating improved quality of care into an improved quality of life for patients with inflammatory bowel disease.

Authors:  Corey A Siegel; John I Allen; Gil Y Melmed
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-05       Impact factor: 11.382

8.  Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge.

Authors:  Sharmeel K Wasan; Jennifer A Coukos; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2011-04-28       Impact factor: 5.325

9.  Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.

Authors:  A J Walsh; M Weltman; D Burger; S Vivekanandarajah; S Connor; M Howlett; G Radford-Smith; W Selby; A S Veillard; M C Grimm; S P L Travis; I C Lawrance
Journal:  J Crohns Colitis       Date:  2013-04-17       Impact factor: 9.071

10.  Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.

Authors:  M Esteve; C Saro; F González-Huix; F Suarez; M Forné; J M Viver
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

View more
  9 in total

Review 1.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

Review 2.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

3.  Lax Prophylaxis: Vaccinating the Inflammatory Bowel Disease Patient.

Authors:  Grigoriy E Gurvits
Journal:  Dig Dis Sci       Date:  2018-01       Impact factor: 3.199

4.  Vaccination of Patients With Inflammatory Bowel Disease.

Authors:  Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

Review 5.  The Human Gut Microbiome - A Potential Controller of Wellness and Disease.

Authors:  Zhi Y Kho; Sunil K Lal
Journal:  Front Microbiol       Date:  2018-08-14       Impact factor: 5.640

6.  Insufficient Knowledge and Vaccination Practice of Inflammatory Bowel Disease Patients in the People's Republic of China.

Authors:  Shuyi Feng; Saizheng Lin; Lingling Ma; Song Xu; Yan Chen
Journal:  Patient Prefer Adherence       Date:  2020-08-24       Impact factor: 2.711

7.  A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease.

Authors:  Guillaume Le Cosquer; Lionel Grangeon; Pauline Rivière; Arthur Berger; Frank Zerbib; David Laharie; Florian Poullenot
Journal:  Therap Adv Gastroenterol       Date:  2022-04-20       Impact factor: 4.802

8.  Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes.

Authors:  Adam V Weizman; Brian Bressler; Cynthia H Seow; Waqqas Afif; Nooran M Afzal; Laura Targownik; Derek M Nguyen; Jennifer L Jones; Vivian Huang; Sanjay K Murthy; Geoffrey C Nguyen
Journal:  J Can Assoc Gastroenterol       Date:  2020-06-09

Review 9.  Update on Vaccinating the Patient With Inflammatory Bowel Disease.

Authors:  Jennifer Coukos; Francis A Farraye
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.